[1]
|
Wells, A.U. (2020) Pamrevlumab in Idiopathic Pulmonary Fibrosis. The Lancet Respiratory Medicine, 8, 2-3.
https://doi.org/10.1016/S2213-2600(19)30339-X
|
[2]
|
Duchemann, B., Annesi-Maesano, I., De Naurois, C.J., Sanyal, S., Brillet, P.Y., Brauner, M., et al. (2017) Prevalence and Incidence of Interstitial Lung Diseases in a Multi-Ethnic County of Greater Paris. European Respiratory Journal, 50, Article ID: 1602419. https://doi.org/10.1183/13993003.02419-2016
|
[3]
|
Esposito, D.B., Lanes, S., Donneyong, M., Holick, C.N., Lasky, J.A., Lederer, D., et al. (2015) Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. American Journal of Respiratory and Critical Care Medicine, 192, 1200-1207. https://doi.org/10.1164/rccm.201504-0818OC
|
[4]
|
Raghu, G., Remy-Jardin, M., Myers, J.L., Richeldi, L., Ryerson, C.J., Lederer, D.J., et al. (2018) Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 198, e44-e68. https://doi.org/10.1164/rccm.201807-1255ST
|
[5]
|
Buendía-Roldán, I., Mejía, M., Navarro, C. and Selman, M. (2017) Idiopathic Pulmonary Fibrosis: Clinical Behavior and Aging Associated Comorbidities. Respiratory Medicine, 129, 46-52. https://doi.org/10.1016/j.rmed.2017.06.001
|
[6]
|
叶俏, 代华平. 特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志, 2016, 39(6): 427-432.
|
[7]
|
Hadjicharalambous, M.R. and Lindsay, M.A. (2020) Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs. International Journal of Molecular Sciences, 21, Article No. 524.
https://doi.org/10.3390/ijms21020524
|
[8]
|
Inoue, Y., Kaner, R.J. and Guiotetal, J. (2020) Diagnosticand Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. Chest, 158, 646-659. https://doi.org/10.1016/j.chest.2020.03.037
|
[9]
|
姚灵, 李南方, 姚晓光, 等. 肺泡表面活性物质相关蛋白A的研究进展[J]. 医学研究杂志, 2019, 48(12): 24-27.
|
[10]
|
Chambers, J.E. and Marciniak, S.J. (2014) Cellular Mechanisms of Endoplasmic Reticulum Stress Signaling in Health and Disease. 2. Protein Misfolding and ER Stress. American Journal of Physiology-Cell Physiology, 307, C657-C670.
https://doi.org/10.1152/ajpcell.00183.2014
|
[11]
|
Liu, L., Qin, J.L., Guo, T., Chen, P., Ouyang, R., Peng, H., et al. (2020) Identification and Functional Characterization of a Novel Surfactant Protein A2 Mutation (p.N207Y) in a Chinese Family with Idiopathic Pulmonary Fibrosis. Molecular Genetics & Genomic Medicine, 8, Article No. e1393. https://doi.org/10.1002/mgg3.1393
|
[12]
|
Seibold, M.A., Wise, A.L., Speer, M.C., Steele, M.P., Brown, K.K., Loyd, J.E., et al. (2011) A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis. New England Journal of Medicine, 364, 1503-1512.
https://doi.org/10.1056/NEJMoa1013660
|
[13]
|
Noth, I., Zhang, Y., Ma, S.F., et al. (2013) Genetic Variants Associated with Idiopathic Pulmonary Fibrosis Susceptibility and Mortality: A Genome-Wide Association Study. The Lancet Respiratory Medicine, 1, 309-317.
https://doi.org/10.1016/S2213-2600(13)70045-6
|
[14]
|
Peljto, A.L., Selman, M., Kim, D.S., Murphy, E., Tucker, L., Pardo, A., et al. (2015) The MUC5B Promoter Polymorphism Is Associated with Idiopathic Pulmonary Fibrosis in a Mexican Cohort But Is Rare among Asian Ancestries. Chest, 147, 460-464. https://doi.org/10.1378/chest.14-0867
|
[15]
|
Wang, C., Zhuang, Y., Guo, W., Cao, L., Zhang, H., Xu, L., et al. (2014) Mucin 5B Promoter Polymorphism Is Associated with Susceptibility to Interstitial Lung Diseases in Chinese Males. PLoS ONE, 9, Article ID: e104919.
https://doi.org/10.1371/journal.pone.0104919
|
[16]
|
宋永娜, 王林纳, 翟建霞, 等. MUC5B启动子rs35705950、rs868903基因多态性与特发性肺纤维化的相关性研究[J]. 临床肺科杂志, 2021, 26(5): 682-686.
|
[17]
|
Kolb, M., White, E.S. and Gauldie, J. (2016) Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 193, 355-357.
https://doi.org/10.1164/rccm.201512-2360ED
|
[18]
|
Nakano, Y., Yang, I.V., Walts, A.D., Watson, A.M., Helling, B.A., Fletcher, A.A., et al. (2016) MUC5B Promoter Variant rs35705950 Affects MUC5B Expression in the Distal Airways in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 193, 464-466. https://doi.org/10.1164/rccm.201509-1872LE
|
[19]
|
Yamasaki, S., Ishikawa, E., Sakuma, M., Hara, H., Ogata, K. and Saito, T. (2008) Mincle Is an ITAM-Coupled Activating Receptor That Senses Damaged Cells. Nature Immunology, 9, 1179-1188. https://doi.org/10.1038/ni.1651
|
[20]
|
Das, B.K., Xia, L., Palandjian, L., Gozani, O., Chyung, Y. and Reed, R. (1999) Characterization of a Protein Complex Containing Spliceosomal Proteins SAPs 49, 130, 145, and 155. Molecular and Cellular Biology, 19, 6796-6802.
https://doi.org/10.1128/MCB.19.10.6796
|
[21]
|
Caspary, F., Shevchenko, A., Wilm, M. and Séraphin, B. (1999) Partial Purification of the Yeast U2 snRNP Reveals a Novel Yeast Pre-mRNA Splicing Factor Required for Pre-Spliceosome Assembly. EMBO J, 18, 3463-3474.
https://doi.org/10.1093/emboj/18.12.3463
|
[22]
|
Martinez, E., Palhan, V.B., Tjernberg, A., Lymar, E.S., Gamper, A.M., Kundu, T.K., et al. (2001) Human STAGA Complex Is a Chromatin-Acetylating Transcription Coactivator That Interacts with Pre-mRNA Splicing and DNA Damage-Binding Factors in Vivo. Molecular and Cellular Biology, 21, 6782-6795.
https://doi.org/10.1128/MCB.21.20.6782-6795.2001
|
[23]
|
Chiffoleau, E. (2018) C-Type Lectin-Like Receptors as Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets. Frontiers in Immunology, 9, Article No. 227. https://doi.org/10.3389/fimmu.2018.00227
|
[24]
|
Gong, W., Guo, K., Zheng, T., Fang, M., Xie, H., Li, W., et al. (2020) Preliminary Exploration of the Potential of Spliceosome-Associated Protein 130 for Predicting Disease Severity in Crohn’s Disease. Annals of the New York Academy of Sciences, 1462, 128-138. https://doi.org/10.1111/nyas.14240
|
[25]
|
Liu, K., Liu, D., Feng, Y., Zhang, H., Zeng, D., Liu, Q., et al. (2020) Spliceosome-Associated Protein 130: A Novel Biomarker for Idiopathic Pulmonary Fibrosis. Annals of Translational Medicine, 8, Article No. 986.
https://doi.org/10.21037/atm-20-4404
|
[26]
|
Martínez, V.G., Moestrup, S.K., Holmskov, U., Mollenhauer, J. and Lozano, F. (2011) The Conserved Scavenger Receptor Cysteine-Rich Super Family in Therapy and Diagnosis. Pharmacological Reviews, 63, 967-1000.
https://doi.org/10.1124/pr.111.004523
|
[27]
|
Gordon, S. and Martinez, F.O. (2010) Alternative Activation of Macrophages: Mechanism and Functions. Immunity, 32, 593-604. https://doi.org/10.1016/j.immuni.2010.05.007
|
[28]
|
Fabriek, B.O., Dijkstra, C.D. and van den Berg, T.K. (2005) The Macrophage Scavenger Receptor CD163. Immunobiology, 210, 153-160. https://doi.org/10.1016/j.imbio.2005.05.010
|
[29]
|
Guo, L., Akahori, H., Harari, E., Smith, S.L., Polavarapu, R., Karmali, V., et al. (2018) CD163+ Macrophages Promote Angiogenesis and Vascular Permeability Accompanied by Inflammation in Atherosclerosis. Journal of Clinical Investigation, 128, 1106-1124. https://doi.org/10.1172/JCI93025
|
[30]
|
Weaver, L.K., Hintz-Goldstein, K.A., Pioli, P.A., Wardwell, K., Qureshi, N., Vogel, S.N., et al. (2006) Pivotal Advance: Activation of Cell Surface Toll-Like Receptors Causes Shedding of the Hemoglobin Scavenger Receptor CD163. Journal of Leukocyte Biology, 80, 26-35. https://doi.org/10.1189/jlb.1205756
|
[31]
|
Hassan, W.A., Baraka, E.A., Elnady, B.M., Gouda, T.M. amd Fouad, N. (2016) Serum Soluble CD163 and Its Association with Various Disease Parameters in Patients with Systemic Sclerosis. European Journal of Rheumatology, 3, 95-100. https://doi.org/10.5152/eurjrheum.2016.15088
|
[32]
|
Zhang, Y., Huang, C., Nie, Y., Liu, Q., Xiao, N., Liu, L., et al. (2021) Soluble CD163 Is a Predictor of Mortality in Patients with Decompensated Cirrhosis. Frontiers in Medicine, 8, Article ID: 698502.
https://doi.org/10.3389/fmed.2021.698502
|
[33]
|
Scott, M.K.D., Quinn, K., Li, Q., Carroll, R., Warsinske, H., Vallania, F., et al. (2019) Increased Monocyte Count as a Cellular Biomarker for Poor Outcomes in Fibrotic Diseases: A Retrospective, Multicentre Cohort Study. Lancet Respiratory Medicine, 7, 497-508. https://doi.org/10.1016/S2213-2600(18)30508-3
|
[34]
|
Yamashita, M., Saito, R., Yasuhira, S., Fukuda, Y., Sasamo, H., Sugai, T., et al. (2018) Distinct Profiles of CD163-Positive Macrophages in Idiopathic Interstitial Pneumonias. Journal of Immunology Research, 2018, Article ID: 1436236.
https://doi.org/10.1155/2018/1436236
|
[35]
|
Yamashita, M., Utsumi, Y., Nagashima, H., Nitanai, H. and Yamauchi, K. (2021) S100A9/CD163 Expression Profiles in Classical Monocytes as Biomarkers to Discriminate Idiopathic Pulmonary Fibrosis from Idiopathic Nonspecific Interstitial Pneumonia. Scientific Reports, 11, Article No. 121 https://doi.org/10.1038/s41598-021-91407-9 35.
|
[36]
|
Ye, Q., Dalavanga, Y., Poulakis, N., Sixt, S.U., Guzman, J. and Costabel, U. (2008) Decreased Expression of Haem Oxygenase-1 by Alveolar Macrophages in Idiopathic Pulmonary Fibrosis. European Respiratory Journal, 31, 1030-1036.
https://doi.org/10.1183/09031936.00125407
|
[37]
|
Ishikawa, N., Hattori, N., Yokoyama, A. and Kohno, N. (2012) Utility of KL-6/MUC1 in the Clinical Management of Interstitial Lung Diseases. Respiratory Investigation, 50, 3-13. https://doi.org/10.1016/j.resinv.2012.02.001
|
[38]
|
Xue, M., Guo, Z., Zhou, L., et al. (2020) Evaluation of the Diagnostic Efficacies of Serological Markers Kl-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia A67. Structure-Function Relationship, 98, 534-545.
|
[39]
|
Guo, L., Yang, Y., Liu, F., Jiang, C., Yang, Y., Pu, H., et al. (2020) Clinical Research on Prognostic Evaluation of Subjects with IPF by Peripheral Blood Biomarkers, Quantitative Imaging Characteristics and Pulmonary Function Parameters. Archivos de Bronconeumología, 56, 365-372. https://doi.org/10.1016/j.arbres.2019.08.020
|
[40]
|
Ohshimo, S., Ishikawa, N., Horimasu, Y., Hattori, N., Hirohashi, N., Tanigawa, K., et al. (2014) Baseline KL-6 Predicts Increased Risk for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 108, 1031-1039.
https://doi.org/10.1016/j.rmed.2014.04.009
|
[41]
|
Aloisio, E., Braga, F., Puricelli, C. and Panteghini, M. (2021) Prognostic Role of Krebs von den Lungen-6 (KL-6) Measurement in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Clinical Chemistry and Laboratory Medicine d, 59, 1400-1408. https://doi.org/10.1515/cclm-2021-0199
|
[42]
|
Zhu, C., Zhao, Y.B., Kong, L.F., Li, Z.H. and Kang, J. (2016) The Expression and Clinical Role of KL-6 in Serum and BALF of Patients with Different Diffuse Interstitial Lung Diseases. Chin. Chinese Journal of Tuberculosis and Respiratory Diseases, 39, 93-97.
|
[43]
|
Bennett, D., Salvini, M., Fui, A., Cillis, G., Cameli, P., Mazzei, M.A., et al. (2019) Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP. Inflammation, 42, 463-470.
https://doi.org/10.1007/s10753-018-00955-2
|
[44]
|
Bonella, F., Ohshimo, S., Boerner, E., et al. (2015) Serum Kl-6 Levels Correlate with Response to Pirfenidone in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 191, Article No. A4398.
|
[45]
|
Bergantini, L., Bargagli, E., Cameli, P., Cekorja, B., Lanzarone, N., Pianigiani, L., et al. (2019) Serial KL-6 Analysis in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Respiratory Investigation, 57, 290-291.
https://doi.org/10.1016/j.resinv.2019.02.001
|